To investigate the pattern of first recurrence of disease in patients with endometrial cancer according to molecular classification, and to assess the independent role of molecular profiling in each ...type of failure.
Retrospective single-center study including patients diagnosed with endometrial cancer stage I-IVB (International Federation of Gynecology and Obstetrics 2009) between December 1994 and May 2022, who underwent primary surgical treatment and had a complete molecular profile. First recurrence was classified as isolated or multiple, and as vaginal, pelvic, peritoneal, nodal, and distant according to its location. The log-rank test and univariate and multivariate adjusted Cox regression models were used for comparison between groups.
A total of 658 patients were included. Recurrence was observed in 122 patients (18.5%) with a recurrence rate of 12.4% among mismatch-repair deficient tumors, 14.5% among non-specific molecular profile, 2.1% among POLE-mutated, and 53.7% among p53-abnormal tumors. Recurrences were found to be isolated in 80 (65.6%) and multiple in 42 (34.4%) patients, with no differences in molecular subtype (p=0.92). Patients with p53-abnormal tumors had a recurrence mainly as distant (28.4%) and peritoneal (21.1%) disease, while patients with non-specific molecular profile tumors presented predominantly with distant failures (10.3%), and mismatch-repair deficient tumors with locoregional recurrences (9.4%).On multivariate analysis, p53-abnormal molecular profile was the only independent risk factor for peritoneal failure (OR=8.54, 95% CI 2.0 to 36.3). Vaginal recurrence was independently associated with p53-abnormal molecular profile (OR=6.51, 95% CI 1.1 to 37.4) and lymphovascular space invasion. p53-abnormal and non-specific molecular profiles were independent predictors for distant recurrence (OR=3.13, 95% CI 1.1 to 8.7 and OR=2.35, 95% CI 1.1 to 5.0, respectively), along with lymphovascular space invasion and high-grade tumors. Molecular profile was not independently associated with pelvic and nodal recurrences.
Endometrial cancer featured different patterns of recurrence depending on the molecular profile. p53-abnormal molecular profiling was the only independent risk factor for peritoneal relapse, while non-specific molecular profile showed a strong association with distant failures.
Malignant peripheral nerve sheath tumors (MPNST) are soft-tissue sarcomas that are the leading cause of mortality in patients with Neurofibromatosis type 1 (NF1). Single chemotherapeutic agents have ...shown response rates ranging from 18% to 44% in clinical trials, so there is still a high medical need to identify chemotherapeutic combination treatments that improve clinical prognosis and outcome. We screened a collection of compounds from the NCATS Mechanism Interrogation PlatE (MIPE) library in three MPNST cell lines, using cell viability and apoptosis assays. We then tested whether compounds that were active as single agents were synergistic when screened as pairwise combinations. Synergistic combinations in vitro were further evaluated in patient-derived orthotopic xenograft/orthoxenograft (PDOX) athymic models engrafted with primary MPNST matching with their paired primary-derived cell line where synergism was observed. The high-throughput screening identified 21 synergistic combinations, from which four exhibited potent synergies in a broad panel of MPNST cell lines. One of the combinations, MK-1775 with Doxorubicin, significantly reduced tumor growth in a sporadic PDOX model (MPNST-SP-01; sevenfold) and in an NF1-PDOX model (MPNST-NF1-09; fourfold) and presented greater effects in TP53 mutated MPNST cell lines. The other three combinations, all involving Panobinostat (combined with NVP-BGT226, Torin 2, or Carfilzomib), did not reduce the tumor volume in vivo at noncytotoxic doses. Our results support the utility of our screening platform of in vitro and in vivo models to explore new therapeutic approaches for MPNSTs and identified that combination MK-1775 with Doxorubicin could be a good pharmacologic option for the treatment of these tumors.
Hybrid neurofibroma/schwannoma of the orbit Salazar-Huayna, Lourdes; Naranjo, Lourdes; Romagosa, Cleofé ...
Revista española de patología,
2023 Apr-Jun, Letnik:
56, Številka:
2
Journal Article
Recenzirano
Hybrid neurofibroma/schwannoma is a rare variant of hybrid peripheral nerve sheath tumours (HPNST). A Medline search up to December 2021 identified only six cases of this tumour in the orbit. We ...report the case of a 78-year-old man who presented with left exophthalmos. Computed tomography showed a left intraconal orbital mass. The clinico-radiological diagnosis was consistent with an intraconal cavernous angioma. Orbitotomy was performed, obtaining an 18×16×11mm mass. Two different morphologies were seen microscopically, diagnostic of hybrid neurofibroma/schwannoma. HPNSTs of the orbit are uncommon and most reported cases showed a hybrid neurofibroma/schwannoma morphology. Hybrid neurofibroma/schwannomas have been associated with neurofibromatosis and schwannomatosis. Local recurrences have been reported. The correct identification of these tumours is important due to their potential use as a syndromic marker.
Introducción: Se describe que las características de la vivienda son un factor importante para llevar a cabo adecuadamente el tratamiento de diálisis peritoneal, sin embargo, no se conoce la real ...relación entre las características de la vivienda y el desarrollo de la peritonitis. Métodos: Se realizó una cohorte retrospectiva que incluyó a todos los pacientes mayores de 18 años de edad que iniciaron el tratamiento de diálisis peritoneal dentro del periodo enero 2002 - diciembre 2011 en el Hospital Nacional Guillermo Almenara Irigoyen. Se describió los tiempos de seguimiento según la fecha de inicio de DP y la primera peritonitis u otros eventos (paso a hemodiálisis, trasplante, muerte o abandono). Las variables fueron evaluadas según su tipo, utilizando estadística descriptiva e inferencial. Resultados: El análisis incluyó a 218 pacientes con una media de edad de 54 años ± 16. El principal lugar donde se realiza el procedimiento de diálisis peritoneal es el dormitorio (77,3%), en su mayoría se encuentra limpio (54,3%), ordenado (71,3%) y despejado (61,8%). Los insumos para el procedimiento se almacenan bajo techo (95,7%) y el mismo paciente ejecuta el tratamiento en la mayoría de los casos (73,1%). La incidencia encontrada fue de 0,17 episodios/paciente-año. La media del tiempo de seguimiento fue de 975 días ± 750. De acuerdo al análisis realizado no se encontró resultados significativos que muestren la relación entre las variables de vivienda y el desarrollo de la primera peritonitis. Conclusión: No se encontró asociación entre las condiciones de vivienda y el desarrollo de peritonitis en pacientes en tratamiento de diálisis peritoneal. Es necesario evaluar y mejorar el programa de visitas domiciliarias
Background: The features of housing are an important risk factor to properly carry out the treatment of peritoneal dialysis. However, the actual situation is that it doesn’t know the real relationship between the characteristics of housing and the development of peritonitis. Methods: A retrospective cohort was made including all patients over 18 years who started PD between the period January 2002 and December 2011 at the Hospital National Guillermo Almenara Irigoyen. The follow-up times was described as the beginning date of use DP and the first peritonitis or other events (hemodialysis, transplant, death or abandonment). The variables were evaluated according to their type using descriptive and inferential statistic. Results: The analysis included 218 patients with a mean age of 54 years ± 16. The main place where the patients did the procedure of peritoneal dialysis is the bedroom (77,3%), most of it is clean (54,3%), organized (71,3%) and clear (61,8%). The inputs for the procedure are stored indoors (95,7%) and the person who executes the procedure is the patient in most cases (73,1%). The observed incidence was 0,17 episodes/patient-year. The mean follow-up time was 975 days ± 750. No significant results were found between the housing conditions and the development of the first peritonitis in patients who are treated by peritoneal dialysis. Conclusion: No association was found between the housing conditions and the development of the first peritonitis. It is necessary to evaluated and improve the home visit program in order to obtain better information of housing condition.
Se reporta dos casos de pancreatitis secundaria a la infección por citomegalovirus confi rmado por reacción
en cadena de la polimerasa en tiempo real (PCR-RT) en pacientes portadores del virus de la ...inmunodefi -
ciencia humana (VIH). Se descartaron otras causas mediante exámenes auxiliares. Ambos pacientes fueron
tratados con ganciclovir y se obtuvo una mejoría tanto clínica como en los exámenes auxiliares. Esta patología
no debe pasar desapercibida en pacientes VIH positivos a pesar de no presentar la característica clínica
de pancreatitis aguda
We report two cases of pancreatitis secondary to cytomegalovirus infections which were tested by reverse
transcription polymerase chain reaction (RT-PCR) in patients with human immunodefi ciency virus (HIV). Other
causes were ruled out by laboratory fi ndings. Both patients were treated with ganciclovir and improved clinically
and as indicated by laboratory fi ndings. This condition should not be ignored in HIV-positive patients in
spite of the absence of the clinical characteristics of acute pancreatitis.
El texto completo de este trabajo no está disponible en el Repositorio Académico UPC por restricciones de la casa editorial donde ha sido publicado.
Introducción Las características de la vivienda ...son un factor importante para llevar a cabo adecuadamente el tratamiento de diálisis peritoneal (DP), sin embargo, no se conoce si estas condicionan la aparición de peritonitis. Métodos Se eligió una cohorte retrospectiva en pacientes que iniciaron DP dentro del periodo enero de 2002-diciembre de 2011 en el Hospital Nacional Guillermo Almenara Irigoyen. Se describieron los tiempos de seguimiento según la fecha de inicio de DP y la primera peritonitis u otros eventos (paso a hemodiálisis, trasplante, muerte o abandono). Las variables fueron evaluadas según su tipo, utilizando estadística descriptiva e inferencial. Resultados El análisis incluyó a 218 pacientes con una media de edad de 54 años ± 16. El principal lugar donde se realiza el procedimiento de DP es el dormitorio (77,3%), en su mayoría se encuentra limpio (54,3%), ordenado (71,3%) y despejado (61,8%). Los insumos para el procedimiento se almacenan bajo techo (95,7%) y el mismo paciente ejecuta el tratamiento en la mayoría de los casos (73,1%). La incidencia encontrada fue de 0,17 episodios/paciente-año. La media del tiempo de seguimiento fue de 975 días ± 750. De acuerdo al análisis realizado, no se encontraron resultados significativos que muestren la relación entre las variables de vivienda y el desarrollo de la primera peritonitis. Conclusión No se encontró asociación entre las condiciones de vivienda y el desarrollo de peritonitis en pacientes en tratamiento de DP. Es necesario evaluar y mejorar el programa de visitas domiciliarias.
PDF
